Recursion Pharmaceuticals, Inc. RXRX Other Receivables
Other Receivables at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s other receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s other receivables?
- Recursion Pharmaceuticals, Inc. (RXRX) reported other receivables of $13.59M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s other receivables changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s other receivables decreased by 70.5% year-over-year, from $46.12M to $13.59M.
- What does other receivables mean?
- This represents miscellaneous claims for cash or other assets not classified under standard trade accounts receivable. It often includes tax refunds, interest receivables, or non-core operational claims. Monitoring this helps identify potential hidden liquidity issues or delays in cash conversion.